[
  {
    "ts": "2025-12-22T16:20:00+00:00",
    "headline": "The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS",
    "summary": "Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained previously lost function and strength, something not previously reported in the natural history of SOD1-ALSBiogen is committed to advancing additional ALS research, including the ongoing QALSODY ATLAS study in pre-symptomatic SOD1-ALS and a robust discovery pipeline in ALS CAMBRIDGE, Mass., Dec",
    "url": "https://finance.yahoo.com/news/journal-american-medical-association-jama-162000803.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3e2f39e6-f6ec-338e-9a6e-be10cc15cf30",
      "content": {
        "id": "3e2f39e6-f6ec-338e-9a6e-be10cc15cf30",
        "contentType": "STORY",
        "title": "The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS",
        "description": "",
        "summary": "Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained previously lost function and strength, something not previously reported in the natural history of SOD1-ALSBiogen is committed to advancing additional ALS research, including the ongoing QALSODY ATLAS study in pre-symptomatic SOD1-ALS and a robust discovery pipeline in ALS CAMBRIDGE, Mass., Dec",
        "pubDate": "2025-12-22T16:20:00Z",
        "displayTime": "2025-12-22T16:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/journal-american-medical-association-jama-162000803.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/journal-american-medical-association-jama-162000803.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T03:31:52+00:00",
    "headline": "Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers",
    "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.",
    "url": "https://finance.yahoo.com/news/therapeutics-stocks-q3-review-biogen-033152389.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "940bc471-baf1-356b-b44f-23a2d605a754",
      "content": {
        "id": "940bc471-baf1-356b-b44f-23a2d605a754",
        "contentType": "STORY",
        "title": "Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers",
        "description": "",
        "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.",
        "pubDate": "2025-12-22T03:31:52Z",
        "displayTime": "2025-12-22T03:31:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BIIB Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI16PwyrPkPhFQpSFVHcpw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IR.mhpWSH09RyIH1vck_EQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/therapeutics-stocks-q3-review-biogen-033152389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/therapeutics-stocks-q3-review-biogen-033152389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]